Astellas’s Long-Term Safety Data Could Boost Fezolinetant’s Approval Chances

 
• By Joseph Haas
hot flash VMS
Astellas hopes to bring a nonhormonal therapy for hot flashes to market • Source: Alamy

More from Clinical Trials

More from R&D